Targeting transcription factors that are intimately involved in endothelial generation and repair such as SOX17 and RUNX1 has the potential to not only shed new light on the pathogenesis of PAH but to significantly change the approach to treating this devastating disease. Here, SOX17 is linked to pulmonary arterial hypertension.